Fevipiprant

Fevipiprant

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Bioavailability	Unaffected by food[1]
Metabolism	Hepatic glucuronidation
Biological half-life	~20 hours
Excretion	Renal (≤30%)
Identifiers
IUPAC name {2-methyl-1-[4-(methylsulfonyl)-2-(trifluoromethyl)benzyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetic acid
CAS Number	872365-14-5
PubChem (CID)	23582412
ChemSpider	23582412
UNII	2PEX5N7DQ4
KEGG	D10631
Chemical and physical data
Formula	C19H17F3N2O4S
Molar mass	426.41 g/mol
3D model (Jmol)	Interactive image
SMILES CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
InChI InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26) Key:GFPPXZDRVCSVNR-UHFFFAOYSA-N

Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D₂ receptor 2 (DP₂ or CRTh2).^[1][2][3]

As of 2016, it is in Phase III^[4] clinical trials for the treatment of asthma.^[5]

See also

• Setipiprant

References

1. Erpenbeck VJ, Vets E, Gheyle L, Osuntokun W, Larbig M, Neelakantham S; et al. (2016). "Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers". Clin Pharmacol Drug Dev. 5 (4): 306–13. doi:10.1002/cpdd.244. PMID 27310331.
2. Sykes DA, Bradley ME, Riddy DM, Willard E, Reilly J, Miah A, Bauer C, Watson SJ, Sandham DA, Dubois G, Charlton SJ. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. Mol Pharmacol. 2016 May;89(5):593-605. doi: 10.1124/mol.115.101832 PMID 26916831
3. Erpenbeck VJ, Popov TA, Miller D, Weinstein SF, Spector S, Magnusson B; et al. (2016). "The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma". Pulm Pharmacol Ther. 39: 54–63. doi:10.1016/j.pupt.2016.06.005. PMID 27354118.
4. https://clinicaltrials.gov/ct2/show/NCT02555683
5. Gonem S, Berair R, Singapuri A, Hartley R, Laurencin M, Bacher G; et al. (2016). "Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial". Lancet Respir Med. doi:10.1016/S2213-2600(16)30179-5.